Close Menu

NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has agreed to acquire ACEA Biosciences for $250 million in cash.

Privately held ACEA, which is based in San Diego, has most recently developed a line of xCELLigence impedance-based, label-free, real-time cell analysis instruments that are used in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. The company also sells a line of NovoCyte and NovoCyte Quanteon high-performance benchtop flow cytometry systems.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.